Dianna S. Howard

3.7k total citations · 2 hit papers
66 papers, 2.3k citations indexed

About

Dianna S. Howard is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Dianna S. Howard has authored 66 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Hematology, 21 papers in Molecular Biology and 19 papers in Oncology. Recurrent topics in Dianna S. Howard's work include Acute Myeloid Leukemia Research (26 papers), Histone Deacetylase Inhibitors Research (10 papers) and Hematopoietic Stem Cell Transplantation (9 papers). Dianna S. Howard is often cited by papers focused on Acute Myeloid Leukemia Research (26 papers), Histone Deacetylase Inhibitors Research (10 papers) and Hematopoietic Stem Cell Transplantation (9 papers). Dianna S. Howard collaborates with scholars based in United States, Greece and Kenya. Dianna S. Howard's co-authors include Craig T. Jordan, Mónica L. Guzmán, Barry Grimes, Randall M. Rossi, David A. Rizzieri, Selina M. Luger, Xiaojie Li, Derick R. Peterson, Sarah J. Neering and Carol Swiderski and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Dianna S. Howard

54 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells

2001 592 citations Mónica L. Guzmán, Barry Grimes et al. Blood profile →
The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells

2005 546 citations Mónica L. Guzmán, Randall M. Rossi et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dianna S. Howard United States	17	1.2k	900	652	558	282	66	2.3k
Astrid Gruber Sweden	34	1.8k 1.5×	643 0.7×	927 1.4×	311 0.6×	343 1.2×	99	3.5k
Utz Krug Germany	25	1.1k 0.9×	980 1.1×	432 0.7×	212 0.4×	233 0.8×	82	2.0k
Daniel Steinbach Germany	26	1.1k 0.9×	497 0.6×	943 1.4×	244 0.4×	336 1.2×	69	2.3k
Jianmin Wang China	26	820 0.7×	1.3k 1.5×	700 1.1×	229 0.4×	415 1.5×	141	2.7k
Angela Ogden United States	24	1.5k 1.2×	808 0.9×	575 0.9×	269 0.5×	99 0.4×	52	2.3k
Ingo Tamm Germany	21	2.7k 2.2×	355 0.4×	980 1.5×	370 0.7×	541 1.9×	42	3.4k
David P. Curley United States	18	2.2k 1.8×	1.0k 1.2×	954 1.5×	336 0.6×	560 2.0×	24	3.5k
Maher Abdul‐Hay United States	13	1.0k 0.8×	1.0k 1.2×	564 0.9×	300 0.5×	396 1.4×	42	2.3k
Jan Eucker Germany	29	1.0k 0.9×	628 0.7×	760 1.2×	284 0.5×	122 0.4×	85	2.5k
Jean‐Pierre Bourquin Switzerland	34	2.0k 1.6×	1.3k 1.5×	889 1.4×	270 0.5×	522 1.9×	129	3.9k

Countries citing papers authored by Dianna S. Howard

Since Specialization

Citations

This map shows the geographic impact of Dianna S. Howard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dianna S. Howard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dianna S. Howard more than expected).

Fields of papers citing papers by Dianna S. Howard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dianna S. Howard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dianna S. Howard. The network helps show where Dianna S. Howard may publish in the future.

Co-authorship network of co-authors of Dianna S. Howard

This figure shows the co-authorship network connecting the top 25 collaborators of Dianna S. Howard. A scholar is included among the top collaborators of Dianna S. Howard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dianna S. Howard. Dianna S. Howard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Klepin, Heidi D., Janet A. Tooze, W. Jack Rejeski, et al.. (2025). Pilot study of an inpatient physical activity intervention for older adults treated intensively for acute myeloid leukemia. Blood Advances. 9(20). 5152–5163.

Vaidya, Rakhee, Hamid Ehsan, Tamara K. Moyo, et al.. (2024). Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell Lymphoma. Transplantation and Cellular Therapy. 30(11). 1082.e1–1082.e10. 4 indexed citations

Salsman, John M., Chandylen L. Nightingale, Mollie Rose Canzona, et al.. (2024). Asking the “Right” Questions about Financial Hardship: Using Cognitive Interviews with Adolescents and Young Adults with Cancer and Their Caregivers to Inform Measure Development. Journal of Adolescent and Young Adult Oncology. 13(5). 760–767. 2 indexed citations

Salsman, John M., Karly M. Murphy, Elizabeth L. Addington, et al.. (2024). Optimization of a digital health intervention to enhance well-being among adolescent and young adult cancer survivors: Design and methods of the EMPOWER full factorial trial. Contemporary Clinical Trials. 149. 107783–107783.

Vaidya, Rakhee, et al.. (2023). Haploidentical Transplant Using a Novel Preparative Regimen: An Update on a New Standard of Care for Patients without HLA Matched Donors. Transplantation and Cellular Therapy. 29(2). S239–S240.

Wall, Sarah, Rebecca L. Olin, Vijaya Raj Bhatt, et al.. (2023). The Transplantation Ecosystem: A New Concept to Improve Access and Outcomes for Older Allogeneic Hematopoietic Cell Transplantation Patients. Transplantation and Cellular Therapy. 29(10). 632.e1–632.e10. 8 indexed citations

Anderson, Rebecca G., Lance D. Miller, Scott Isom, et al.. (2022). Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia. Nature Communications. 13(1). 1673–1673. 28 indexed citations

Vaidya, Rakhee, et al.. (2021). Development and Implementation of Outpatient CAR-T Program at the Wake Forest Baptist Comprehensive Cancer Center. Transplantation and Cellular Therapy. 27(3). S315–S315. 1 indexed citations

Salsman, John M., Suzanne C. Danhauer, Justin B. Moore, et al.. (2021). Systematic review of financial burden assessment in cancer: Evaluation of measures and utility among adolescents and young adults and caregivers. Cancer. 127(11). 1739–1748. 27 indexed citations

10.

Pardee, Timothy S., Susan Lyerly, Sarah Dralle, et al.. (2020). Frontline Selinexor and Chemotherapy Is Highly Active in Older Adults with Acute Myeloid Leukemia (AML). Blood. 136(Supplement 1). 24–25. 4 indexed citations

11.

Howard, Dianna S., et al.. (2019). PCN179 TREOSULFAN-BASED CONDITIONING VS BUSULFAN-BASED CONDITIONING FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AML OR MDS — A UK COST-UTILITY ANALYSIS. Value in Health. 22. S471–S471. 1 indexed citations

12.

Pardee, Timothy S., Rebecca G. Anderson, Scott Isom, et al.. (2018). A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia. Clinical Cancer Research. 24(9). 2060–2073. 80 indexed citations

13.

Saeed, Hayder, et al.. (2018). Age adjusted hematopoietic stem cell transplant comorbidity index predicts survival in a T-cell depleted cohort ☆. Hematology/Oncology and Stem Cell Therapy. 11(2). 90–95. 1 indexed citations

14.

Hari, Parameswaran, Donna Reece, Jasleen K. Randhawa, et al.. (2018). Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival. Bone Marrow Transplantation. 54(2). 293–299. 10 indexed citations

15.

Powell, Bayard L., et al.. (2017). Acute Myeloid Leukemia in Pregnancy. Blood. 130. 5035–5035.

16.

Pardee, Timothy S., Scott Isom, Leslie R. Ellis, et al.. (2017). Interim Analysis of a Single Arm Phase II Study of Cpi-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML. Blood. 130. 2626–2626. 1 indexed citations

17.

Powell, Bayard L., Dianna S. Howard, Leslie R. Ellis, et al.. (2017). Incidence of Bleeding Events in Acute Myeloid Leukemia (AML) Patients Receiving Anticoagulation Therapy for Treatment of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) Who Are Also Undergoing Induction or Re-Induction Therapy. Blood. 130. 2091–2091. 1 indexed citations

18.

Howard, Dianna S., Jane L. Liesveld, Gordon L. Phillips, et al.. (2013). A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. Leukemia Research. 37(11). 1502–1508. 21 indexed citations

19.

Lekakis, Lazaros J., Julie A. Ribes, Gregory J. Davis, et al.. (2009). Fatal Rhizopus Pneumonia in Allogeneic Stem Cell Transplant Patients Despite Posaconazole Prophylaxis: Two Cases and Review of the Literature. Biology of Blood and Marrow Transplantation. 15(8). 991–995. 38 indexed citations

20.

Guzmán, Mónica L., Carol Swiderski, Dianna S. Howard, et al.. (2002). Preferential induction of apoptosis for primary human leukemic stem cells. Proceedings of the National Academy of Sciences. 99(25). 16220–16225. 334 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact